Opportunity overview
CAR-T treatment called Obecel developed to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL) which has recently become available to patients. The decision which treatment is most suitable applicable to a specific age group is a clinical one that would be decided by a Multi-Disciplinary Team (MDT). The product should meet strict NHS England standards for cryogenic storage and handling and RMH has such credentials.
Classification
No classification was supplied.
Lots
- Lot 1Value not stated
Documents and notices
- Transparency notice on Find a TenderOpen source ↗